Clinical Trial Update: Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating Optune plus Bevacizumab in bevacizumab-refractory recurrent glioblastoma; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma
• Gliosarcoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• OPTUNE

Snippet

Sponsor: RTOG Foundation, Inc. | Conditions: Glioblastoma, Glioma | Phase 2 | Status: TERMINATED | Results posted: 2020-11-17